IL2 and plasma cell myeloma: Since the first observation of the ability of aminobisphosphonate to selectively expand Vδ2Vγ9 T cells in multiple myeloma patients (101), several clinical trials have been conducted in solid and hematological cancers using zoledronate (ZOL) and low dose IL-2 for either in vivo or ex vivo expansion of Vδ2Vγ9 cells (30, 49).